Skip to content

Adaptive Biotechnologies ADPT Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$49.64M+65.0%-$59.46M+62.7%-$79.6M+59.3%-$121.24M+43.2%-$141.89M+34.0%
$15.24M-10.7%$16.13M-8.1%$16.39M-11.4%$16.57M-15.7%$17.07M-16.0%
$51.26M-0.4%$51.48M-4.0%$51.6M-8.4%$51.86M-10.8%$51.46M-17.7%
-$29.09M+65.9%-$48.04M+49.5%-$60.53M+44.8%-$80.47M+37.8%-$85.34M+37.0%
$2.5M-26.8%$2.96M-19.2%$2.4M-50.8%$2.34M-68.0%$3.41M-63.2%
$68.32M+16.0%$56.33M-29.4%$58.86M-47.1%
$32.45M+475%$30.4M+12,515%$8.87M+4,314%$7.23M+3,961%$5.65M+249%
$26.93M$22.37M
-$30.95M+65.1%-$50.36M+49.1%-$62.94M+45.1%-$82.81M+39.4%-$88.76M+38.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Adaptive Biotechnologies generate?
Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
What is Adaptive Biotechnologies's free cash flow?
After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
Where does Adaptive Biotechnologies's cash flow data come from?
Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.